HETEROCYCLIC COMPOUNDS AND USES THEREOF

• US 20190330240A1
• Filed: 03/01/2019
• Published: 10/31/2019
• Est. Priority Date: 10/03/2014
• Status: Active Grant

• Current Assignee: Infinity Pharmaceuticals, Inc.
• Original Assignee: Infinity Pharmaceuticals, Inc.
• Inventors: Castro, Alfredo C., Evans, Catherine A., Tremblay, Martin R.
• Granted Patent: US 10,941,162 B2
• Time in Patent Office: Days
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07D 491/04 Ortho-condensed systems
• CPC Class Codes: C07D 495/04 Ortho-condensed systems
• CPC Class Codes: C07D 498/04 Ortho-condensed systems
• CPC Class Codes: C07D 513/04 Ortho-condensed systems
• CPC Class Codes: C07D 519/00 Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Claims

1. A compound of Formula I′

or Formula II′

;

2. The compound of claim 1, which is a compound of Formula I′

;

3. The compound of claim 1, which is a compound of Formula II′

;

7. The compound of claim 1, wherein W^d is

8. The compound of claim 2, wherein the compound of Formula I′

is a compound of formula I;

9. The compound of claim 3, wherein the compound of Formula II′

is a compound of formula II;

16. The compound of claim 1, wherein A is 6-membered heterocycle or carbocycle and B is 6-membered heterocycle or carbocycle.

19. The compound of claim 16, wherein the compound of Formula I′

is a compound of the formula;

20. The compound of claim 16, wherein the compound of Formula I′

is a compound of the formula;

26. The compound of claim 16, wherein the compound of Formula I′

is a compound of the formula;

27. The compound of claim 16, wherein the compound of Formula I′

is a compound of the formula;

33. The compound of claim 1, wherein A is 6-membered heterocycle or carbocycle and B is 5-membered heterocycle or carbocycle.

36. The compound of claim 33, wherein the compound of Formula I′

is a compound of the formula;

37. The compound of claim 33, wherein the compound of Formula I′

is a compound of the formula;

43. The compound of claim 33, wherein the compound of Formula I′

is a compound of the formula;

44. The compound of claim 33, wherein the compound of Formula I′

is a compound of the formula;

50. The compound of claim 1, wherein A is 5-membered heterocycle or carbocycle and B is 6-membered heterocycle or carbocycle.

53. The compound of claim 50, wherein the compound of Formula I′

is a compound of the formula;

54. The compound of claim 50, wherein the compound of Formula I′

is a compound of the formula;

65. The compound of claim 1, wherein A is 5-membered heterocycle or carbocycle and B is 5-membered heterocycle or carbocycle.

67. The compound of claim 65, wherein the compound of Formula I′

is a compound of the formula;

68. The compound of claim 65, wherein the compound of Formula I′

is a compound of the formula;

83. The compound of claim 1, wherein

84. The compound of claim 1, wherein the compound is a compound selected from Table 1, Table 2, Table 3, and Table 4, or a pharmaceutically acceptable form thereof.

85. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable expedient.

86. The pharmaceutical composition of claim 85, further comprises one or more therapeutic agent.

87. A method of treating or preventing a PI3K mediated disorder in a subject comprising administering an effective amount of a compound of claim 1 to the subject.

88. A kit comprising a compound of claim 1.

4-6. -6. (canceled)

10-15. -15. (canceled)

17-18. -18. (canceled)

21-25. -25. (canceled)

28-32. -32. (canceled)

34-35. -35. (canceled)

38-42. -42. (canceled)

45-49. -49. (canceled)

51-52. -52. (canceled)

55-64. -64. (canceled)

66. (canceled)

69-82. -82. (canceled)